Conmed Corporation · NYSE:CNMD
Conmed — J.P. Morgan 44th Annual Healthcare Conference (January 2026)
16 slides from Conmed's conference presentation, Jan 12, 2026
Slide 1: J.P. Morgan 44th Annual Healthcare Conference
J.P. Morgan 44 th Annual Healthcare Conference Pat J. Beyer President and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer January 12 th , 2026
Slide 2: Forward-Looking Information
Forward - Looking Information This presentation may contain forward - looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward - looking st
Slide 3: CONMED Vision
Empower healthcare providers worldwide to deliver exceptional outcomes for patients. Focus behind the Vision People, Products, Profitability CONMED Vision 3
Slide 4: CONMED At a Glance
CONMED At a Glance September 2025 YTD Revenue Mix Sports Medicine (MSD to HSD) Ortho Capital & Related Disp. (LSD to MSD) Foot & Ankle (HSD to DD) AirSeal & Direct Smoke Evac. (HSD TO DD) Surgical Instruments (LSD to MSD) Other (Decline to Flat) Estimated 2026 Product Mix & Mid - Term Expected Reven
Slide 5: Consistent Execution Driving Long-Term Growth
*The reconciliations to GAAP numbers are included in our historical earnings releases and related 8 - K filings **2022 results were negatively impacted by Q4 2022 warehouse issue Consistent Execution Driving Long - Term Growth 5 Revenue (in millions) Adjusted EPS* $764 $796 $860 $955 $862 $1,011 $1,
Slide 6: High-Growth Platforms Shaping Our Future
AirSeal Advanced insufflation system clinically proven to improve surgical outcomes Buffalo Filter Surgical smoke evacuation portfolio positioned for growth with legislative tailwinds and product innovation BioBrace Reinforced bioinductive implant used in 70+ orthopedic and foot & ankle procedures H
Slide 7: AirSeal Clinically Differentiated Insufflation System
Benefitting Patients & Providers: • Delivers stable, single - digit low pressure • Continuous smoke evacuation and valve - less trocar improves visibility and reduces procedure time 1,12,18,19* • Clinically proven to shorten patient length of stay and reduce pain 1 - 3,7,9,13,16,17* • Shorter length
Slide 8: Buffalo Filter Advanced Smoke Evacuation
Strong Markets + Strong Platform: • Global smoke evacuation as standard of care represents a $1B+ market opportunity • International market opportunity led by early expansion in Nordic countries & Canada • Next - gen PlumeSafe ® X5 launched in 1H25 Expected Continued Tailwinds: • 20 U.S. states, cov
Slide 9: BioBrace High-Need Sports Medicine Market
Large Market, Significant Unmet Need: • More than 3.7M orthopedic soft - tissue procedures expected annually in the U.S. by 2029 driven by an active, aging population ⁽ ⁴ ⁾ • Biologic limitations and current repair techniques contribute to high re - tear and incomplete healing across key procedures
Slide 10: BioBrace: The Reinforced Bioinductive Advantage
Unique Differentiation : • Only implant FDA - cleared for both mechanical reinforcement and bioinductivity (facilitate healing) • Broad FDA indication that supports use in 70+ procedures across orthopedics and foot & ankle • New BioBrace® RC delivery system (2025) simplifies rotator cuff repairs Cli
Slide 11: Financial Strength Driving Consistent Cash Flow
Organic Investment Priorities: • R&D and product innovation • Manufacturing & supply chain optimization • Commercial expansion & technology Inorganic Investment Priorities: • Accretive to existing portfolio • Complementary technologies and markets Improving Leverage & Durable Cash Flow: • Lower leve
Slide 12: Preliminary Financial Guidance Full Year 2026
Preliminary Financial Guidance Full Year 2026 Revenue $1,423M to $1,450M ~4% to ~6% growth constant currency Organic Constant Currency $(78M) to $(82M) Impact of G.I. Divestiture $0M to ~$7M 0 to 50 BP tailwind Estimated Foreign Currency Impact $1,345M to $1,375M Total Reported Revenue Adjusted EPS
Slide 13: Together We Are Making A Difference for a Better Tomorrow
Partners with the United Way to serve communities where we operate in the U.S. CONMED manufacturing operations have recycling programs including eScrap , metal, cardboard, plastic, and paper. Effective board leadership and independent oversight. 100% independent standing board committees and regular
Slide 14: CONMED Driven to Win
» Leveraging Growth Drivers Focusing on high - growth, high - margin products: AirSeal , Buffalo Filter, BioBrace » Optimizing Portfolio Exiting gastroenterology to align resources with minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair » Transforming Supply Chain Drivin
Slide 15: AirSeal References (From Slide 7)
AirSeal ® References (From Slide 7) 1.Ramshaw B, Forman B, Heidel E, Dean J, Gamenthaler A, Fabian M. A Clinical Quality Improvement (CQI) Project to Improve Pain After Laparoscopic Ventral Hernia Repair. Surg Tech no l Int. 2016;29:125 - 130. 2.Foley CE, Ryan E, Huang JQ. Less is more: clinical imp
Slide 16: Free Cash Flow Conversion Calculation (From Slide 11)
Free Cash Flow Conversion Calculation (From Slide 11) 16 2025 YTD** 2024 2023 2022 2021 2020 2019 $ 124,353 $ 166,968 $ 125,348 $ 33,365 $ 111,770 $ 64,531 $ 95,133 Operating Cash Flow (14,695) (13,084) (19,032) (21,785) (14,866) (13,013) (20,066) Less: Capital Expenditures $ 109,658 $ 153,884 $ 106
CONMED — J.P. Morgan 44th Annual Healthcare Conference (January 2026) on 6ix